Correspondence 0001493152-25-002058 from Hepion Pharmaceuticals, Inc. (HEPA)

Hepion Pharmaceuticals, Inc.
Date: Jan. 14, 2025 · CIK: 0001583771 · Accession: 0001493152-25-002058

View on Edgar

AI Filing Summary & Sentiment

File numbers found in text: 333-284052

Date

Jan. 14, 2025

Author

Director

Form

CORRESP

Company

Hepion Pharmaceuticals, Inc.

Letter

Laidlaw & Company (UK) Ltd.

5th Ave,

New York, NY 10175

January 14,

VIA EDGAR

U.S. Securities and Exchange Commission

Division of Corporation Finance

F Street, N.E.

Washington, D.C. 20549

Re: Hepion Pharmaceuticals, Inc.

Registration Statement on Form S-1, as amended

File No: 333-284052

Ladies and Gentlemen:

Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended (the “Securities Act”), Laidlaw & Company (UK) Ltd. as Placement Agent, hereby requests acceleration of the effective date of the above-referenced Registration Statement so that it will become effective at 5:00pm Eastern Time on January 15, 2025 or as soon thereafter as practicable.

Very
truly yours,
Laidlaw
& Company (UK) Ltd.

Show Raw Text

CORRESP
1
filename1.htm

Laidlaw
& Company (UK) Ltd.

521
5th Ave,

New
York, NY 10175

  January 14,
  2025

VIA
EDGAR

U.S.
Securities and Exchange Commission

Division
of Corporation Finance

100
F Street, N.E.

Washington,
D.C. 20549

    Re:
    Hepion
    Pharmaceuticals, Inc.

    Registration
    Statement on Form S-1, as amended

    File
    No: 333-284052

Ladies
and Gentlemen:

Pursuant
to Rule 461 promulgated under the Securities Act of 1933, as amended (the “Securities Act”), Laidlaw & Company (UK) Ltd.
as Placement Agent, hereby requests acceleration of the effective date of the above-referenced Registration Statement so that
it will become effective at 5:00pm Eastern Time on January 15, 2025 or as soon thereafter as practicable.

    Very
    truly yours,

    Laidlaw
    & Company (UK) Ltd.

    By:
    /s/
    Hugh Regan

    Name:
    Hugh
Regan

    Title:
    Executive
    Director

SecProbe.io